Lamotrigine or Topiramate
Based on the available evidence, lamotrigine is the most effective alternative antiepileptic drug for primary generalized seizure disorder after valproate and levetiracetam, with topiramate as a close second option. 1
Evidence Supporting Lamotrigine
The American Academy of Neurology/American Epilepsy Society guidelines specifically state that lamotrigine is effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children 1. In Class I evidence trials, lamotrigine demonstrated:
- 50% responder rate in generalized tonic-clonic seizures (GTCCs) in patients aged 15-50 years 1
- 33% reduction in absence seizures in the same population 1
- Discontinuation rates of only 8% due to adverse events 1
More recent high-quality evidence from a 2017 Cochrane network meta-analysis confirms that lamotrigine is a suitable alternative to sodium valproate for individuals with generalized tonic-clonic seizures, particularly important for those of childbearing potential 2. A 2018 network meta-analysis showed lamotrigine had the highest probability (61%) of achieving seizure freedom in generalized tonic-clonic, tonic, and clonic seizures 3.
Evidence Supporting Topiramate
Topiramate also has strong Level A evidence for primary generalized seizures:
- 56% responder rate for GTCCs at doses of approximately 6 mg/kg/day versus 20% for placebo 1
- Similar discontinuation rates to placebo (2.6% vs 2.4%) 1
- Effective for both adults and children with idiopathic generalized epilepsy 1
Clinical Decision Algorithm
Choose lamotrigine if:
- Patient is female of childbearing age (valproate contraindicated)
- Cognitive function preservation is priority (better cognitive profile than topiramate)
- Patient has absence seizures as part of syndrome (lamotrigine effective for both GTCCs and absence)
Choose topiramate if:
- Patient has failed lamotrigine
- Patient has comorbid migraine (topiramate has dual indication)
- Drop attacks are prominent feature (particularly effective for Lennox-Gastaut syndrome) 1
Important Caveats
Rash risk with lamotrigine: Occurs in 10-27% of patients 1. Requires slow titration, especially if patient is on valproate (use 50% of standard dose) 1. Stevens-Johnson syndrome, though rare, has been reported 1.
Topiramate cognitive effects: Common adverse events include cognitive slowing, word-finding difficulties, and weight loss. These occur more frequently than with lamotrigine and may limit tolerability despite good efficacy 1.
Avoid phenobarbitone: This older agent consistently performs worse than all other treatments for both efficacy and tolerability across all seizure types 2.
Dosing Considerations
Lamotrigine: Start 50-150 mg/day (lower if on valproate), titrate slowly over weeks to 300-500 mg/day 1
Topiramate: Target dose 6 mg/kg/day (approximately 400-600 mg/day in adults), with efficacy plateauing above 400 mg/day 1
The evidence clearly positions lamotrigine as the preferred third-line option after valproate and levetiracetam, with topiramate as an effective alternative when lamotrigine is not suitable or has failed.